Recommended criteria for the evaluation of bacterial mutagenicity data (Ames test).


Journal

Mutation research. Genetic toxicology and environmental mutagenesis
ISSN: 1879-3592
Titre abrégé: Mutat Res Genet Toxicol Environ Mutagen
Pays: Netherlands
ID NLM: 101632149

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 07 03 2019
accepted: 11 07 2019
entrez: 12 11 2019
pubmed: 12 11 2019
medline: 3 4 2020
Statut: ppublish

Résumé

A committee was constituted within the International Workshop on Genetic Toxicology Testing (IWGT) to evaluate the current criteria for a valid Ames test and to provide recommendations for interpretation of test results. Currently, determination of a positive vs. a negative result is made by applying various data evaluation procedures for comparing dosed plates with the concurrent solvent control plates. These evaluation procedures include a requirement for a specific fold increase (2- or 3-fold, specific to the bacterial strain), formal statistical procedures, or subjective (expert judgment) evaluation. After extensive discussion, the workgroup was not able to reach consensus recommendations in favor of any of these procedures. There was a consensus that combining additional evaluation criteria to the comparison between dosed plates and the concurrent solvent control plates improves test interpretation. The workgroup recommended using these additional criteria because the induction of mutations is a continuum of responses and there is no biological relevance to a strict dividing line between a positive (mutagenic) and not-positive (nonmutagenic) response. The most useful additional criteria identified were a concentration-response relationship and consideration of a possible increase above the concurrent control in the context of the laboratory's historical solvent control values for the particular tester strain. The workgroup also emphasized the need for additional testing to resolve weak or inconclusive responses, usually with altered experimental conditions chosen based on the initial results. Use of these multiple criteria allowed the workgroup to reach consensus on definitions of "clear positive" and "clear negative" responses which would not require a repeat test for clarification. The workgroup also reached consensus on recommendations to compare the responses of concurrent positive and negative controls to historical control distributions for assay acceptability, and the use of control charts to determine the validity of the individual test.

Identifiants

pubmed: 31708073
pii: S1383-5718(19)30077-4
doi: 10.1016/j.mrgentox.2019.07.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

403074

Informations de copyright

Published by Elsevier B.V.

Auteurs

Dan D Levy (DD)

US Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD, 20740, USA. Electronic address: Dan.levy@fda.hhs.gov.

Errol Zeiger (E)

Errol Zeiger Consulting, Chapel Hill, NC, 27514, USA.

Patricia A Escobar (PA)

Merck & Co. Inc., West Point, PA, USA.

Atsushi Hakura (A)

Tsukuba Drug Safety, Eisai Co., Ltd., Tsukuba, Ibaraki, 300-2635, Japan.

Bas-Jan M van der Leede (BM)

Non-Clinical Safety, Janssen Research & Development, a Division of Janssen Pharmaceutica N.V., Beerse, Belgium.

Masayuki Kato (M)

CMIC Pharma Science Co., Ltd., Hokuto, Yamanashi, Japan.

Martha M Moore (MM)

Ramboll US Corporation, Little Rock, AR, 72201, USA.

Kei-Ichi Sugiyama (KI)

Division of Genetics and Mutagenesis, National Institute of Health Sciences, Kawasaki, Kanagawa, 210-9501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH